| 08:05a | ORAGENICS, INC. : to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium | BU |
| 08:05a | LexaGene Holdings Inc. Joins The Stock Day Podcast to Announce Successful Beta Testing | NE |
| 08:04a | ELI LILLY AND : Steven Jones and Leigh Ann Pusey to Serve on The Mind Trust Board of Directors | AQ |
| 08:04a | VERTEX PHARMACEUTICALS : FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment | BU |
| 08:03a | LEXAGENE : Joins The Stock Day Podcast to Announce Successful Beta Testing | AQ |
| 08:01a | AMAG PHARMACEUTICALS : Announces Grant of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4) | AQ |
| 08:01a | ASSERTIO THERAPEUTICS : to Present at the 17th Annual Morgan Stanley Global Healthcare Conference | AQ |
| 08:01a | MERSANA THERAPEUTICS : Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and Non-Small Cell Lung Cancer | AQ |
| 08:01a | NUCANA : Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis | AQ |
| 08:01a | RESTORATION ROBOTICS : reg; Announces the ARTAS iX™ System to be Featured on the Good Day New York Show | AQ |
| 08:01a | CANCER GENETICS : Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update | AQ |
| 08:01a | BIOXCEL THERAPEUTICS : Announces Award of Grant by U.S. Department of Defense's (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501 | AQ |
| 08:01a | EIGER BIOPHARMACEUTICALS : Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection | PR |
| 08:01a | SOLITON : Announces Positive Results Demonstrated from Longer RAP Treatment | PR |
| 08:01a | CENTENE : To Present At Wells Fargo 2019 Healthcare Conference | PR |
| 07:41a | AGILENT TECHNOLOGIES : $64,220 Federal Contract Awarded to Agilent Technologies | AQ |
| 07:37a | VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 07:31a | Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019 | GL |
| 07:31a | New Pilot Clinical Study Results Demonstrate that Addition of VIVUS' Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone | GL |
| 07:31a | Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients | GL |
| 07:21a | HARVARD BIOSCIENCE : $26,610 Federal Contract Awarded to Harvard Bioscience | AQ |
| 07:11a | HIGH TIDE : Exhibits and Presents Canna Cabana at AMO Conference in Ottawa | AQ |
| 07:08a | AXSOME THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 07:07a | TONIX PHARMACEUTICALS HOLDING CORP. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 07:03a | PREMIER INC. : Reports Fiscal 2019 Fourth-Quarter and Full-Year Results | BU |
| 07:01a | SAVE THE DATE : NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019 | AQ |
| 07:01a | TRUTRACE TECHNOLOGIES : and Anandia to Collaborate on Analytical and Genetic Testing for Cannabis | AQ |
| 07:01a | AVRICORE HEALTH : Corporate Update and Private Placement Extension | AQ |
| 07:01a | CANOPY GROWTH : Receives Key Extraction Licence | PR |
| 07:01a | PROVENTION BIO : Announces Key Addition to its Leadership Team | PR |
| 07:01a | Axsome Therapeutics Appoints David Marek as Chief Commercial Officer | GL |
| 07:01a | Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update | GL |
| 07:01a | uniQure Announces Leadership Promotions and Executive Transition | GL |
| 07:01a | Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD | GL |
| 07:01a | THE PFIZER FOUNDATION : Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance | BU |
| 06:59a | MEDTRONIC : Fiscal 1Q Earnings Snapshot | AQ |
| 06:53a | LANNETT : To Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Tuesday, August 27 | PR |
| 06:52a | BENCHMARK : wins prestigious Aquaculture Innovation Award | PU |
| 06:51a | MEDTRONIC PLC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 06:45a | Medtronic Reports First Quarter Financial Results | GL |
| 06:43a | AERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 06:31a | AERIE PHARMACEUTICALS : Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema | BU |
| 06:10a | ELANCO ANIMAL HEALTH INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 06:08a | SYNLOGIC, INC. : Regulation FD Disclosure, Other Events (form 8-K) | AQ |
| 06:07a | JOHNSON & JOHNSON : Oklahoma County files petition against opioid manufacturers | AQ |
| 06:06a | TENET HEALTHCARE CORP : Change in Directors or Principal Officers (form 8-K) | AQ |
| 06:06a | HST GLOBAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) | AQ |
| 06:05a | SAREPTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 06:05a | ELANCO ANIMAL HEALTH : Bayer to sell animal health unit to Elanco for $7.6 billion | AQ |
| 06:03a | SYNLOGIC : Discontinues Development of SYNB1020 to Treat Hyperammonemia | BU |
United Kingdom
France
Deutschland
Schweiz (DE)
Prev.
